STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits

International Journal of Oncology

Volumn 44, Issue 2, 2014, Pages 403-411

  Chung, Seyung S ^a   Giehl, Nolan ^a   Wu, Yanyuan ^a,b   Vadgama, Jaydutt V ^a,b  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Cancer stem cell; Epithelial mesenchymal transition; ER; HER2; STAT3

Indexed keywords

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CYCLIC S-OXIDES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IMMUNOPRECIPITATION; MICE; NEOPLASTIC STEM CELLS; NIH 3T3 CELLS; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84894432430     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2195     Document Type: Article

References (36)

1. Wu Y, Elshimali Y, Sarkissyan M, Mohamed H, Clayton S and Vadgama JV: Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer. Am J Cancer Res 2: 104-115, 2012.
2. Hartman Z, Yang X, Glass O, Lei G, Osada T, Dave SS, et al: HER2 overexpression elicits proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. Cancer Res 71: 4380-4391, 2011.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ulrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177-182, 1987. (Pubitemid 17231334)
4. Hynes NE and Stern DF: The biology of erbB-2/neu/HER2 and its role in cancer. Biochim Biophys Acta 1198: 165-184, 1994.
5. Yarden Y: Biology of HER2 and its importance in breast cancer. Oncology 61: 1-13, 2001.
6. Pegram MD, Konecny G and Slamon DJ: The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of Herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 103: 57-75, 2000.
7. Zhang W, Ding W, Chen Y, Feng M, Ouyang Y, Yu Y and He Z: Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF-7 breast cancer cells. Acta Biochim Biophys Sin (Shanghai) 43: 647-653, 2011.
8. Siddiqa A, Long L, Li L, Marciniak R and Kazhdan I: Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signaling pathways. BMC Cancer 8: 129, 2008.
9. Gemmete JJ and Mukherji SK: Trastuzumab (herceptin). Am J Neuroradiol 32: 1373-1374, 2011.
10. Harbeck N, Pegram MD, Rüschoff J and Möbus V: Targeted therapy in metastatic breast cancer: the HER2/neu oncogene. Breast Care (Basel) 5 (Suppl 1): 3-7, 2010.
11. Hubalek M, Brunner C, Matthä K and Marth C: Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment. Wien Med Wochenschr 160: 506-512, 2010.
12. Cheng GZ, Zhang W, Sun M, Wang Q, Coppola D, Mansour M, et al: Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem 283: 14665-14673, 2008.
13. Lin L, Hutzen B, Zuo M, Ball S, Deangelis S and Foust E: Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 70: 2445-2454, 2010.
14. Armanious H, Gelebart P, Mackey J, Ma Y and Lai R: STAT3 upregulates the protein expression and transcriptional activity of β-catenin in breast cancer. Int J Clin Exp Pathol 3: 654-664, 2010.
15. Zhong Z, Wen Z and Darnell J: Stat3: a STAT3 family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95-98, 1994. (Pubitemid 24144493)
16. Hart JR, Liao L, Yates J and Vogt P: Essential role of Stat3 in PI3K-induced oncogenic transformation. Proc Natl Acad Sci USA 108: 13247-13252, 2011.
17. Yang Z, Cai J, Xie S, Li G, Song W, Yan Q, Yan L and Zhang F: Therapeutic effects of signal transducer and activator of transcription 3 siRNA on human breast cancer in xenograft mice. Chin Med J 124: 1854-1861, 2011.
18. Yi EH, Lee CS, Lee JK, Lee YJ, Shin MK, Cho CH, et al: STAT3-RANTES autocrine signaling is essential for tamoxifen rsistance in human breast cancer cells. Mol Cancer Res 11: 31-42, 2013.
19. - stem cell-like breast cancer cells in human tumors. J Clin Invest 121: 2723-2735, 2011.
20. Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cufi S, Del Barco S, Lopez-Bonet E, et al: Dynamic emergence of the mesenchymal CD44pos/CD24neg/low phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochem Biophys Res Commun 397: 27-33, 2010.
21. Fang X, Cai Y, Liu J, Wang Z, Wu Q, Zhang Z, et al: Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like self-renewal. Oncogene 30: 4707-4720, 2011.
22. Berishaj M, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, Gerald W, et al: Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 9: R32, 2007.
23. Schust J, Sperl B, Hollis A, Mayer T and Berg T: Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 13: 1235-1242, 2006. (Pubitemid 44750735)
24. Kong D, Li Y, Wang Z and Sarkar FH: Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins? Cancers (Basel) 3: 716-729, 2011.
25. Sato T, Neilson LM, Peck AR, Liu C, Tran T, Witkiewicz A, et al: Signal transducer and activator of transcription-3 and breast cancer prognosis. Am J Cancer Res 1: 347-355, 2011.
26. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Panday MK, Kunnunmakkara AB, et al: Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann NY Acad Sci 1091: 151-169, 2006. (Pubitemid 47092233)
27. Masuda M, Wakasaki T, Suzui M, Toh S, Joe AK and Weinstein IB: Stat3 orchestrates tumor development and progression: the Achilles' heel of head and neck cancers? Curr Cancer Drug Targets 10: 117-126, 2010.
28. Takeda K, Noguchi K, Shi W, et al: Targeted disruption of the mouse STAT3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 94: 3801-3804, 1997. (Pubitemid 27180453)
29. Akira S: Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 19: 2607-2611, 2000.
30. Ho JN, Kang GY, Lee SS, Kim J, Bae IH, Hwang SG and Um HD: Bcl-XL and STAT3 mediate malignant actions of gamma-irradiation in lung cancer cells. Cancer Sci 101: 1417-1423, 2010.
31. Hsu H-S, Lin JH, Hsu TW, Su K, Wang CW, Yang KY, et al: Mesenchymal stem cells enhance lung cancer initiation through activation of IL-6/JAK2/STAT3 pathway. Lung Cancer 75: 167-177, 2012.
32. Floor S, van Staveren WC, Larsimont D, Dumont JE and Maenhaut C: Cancer cells in epithelial-to-mesenchymal transition and tumor propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene 30: 4609-4621, 2011.
33. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A and Zhou AY: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715, 2008. (Pubitemid 351636299)
34. Takebe N, Warren RQ and Ivy SP: Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res 13: 211, 2011.
35. Al-Ejeh F, Smart CE, Morrison BJ, Chenevix-Trench G, Lopez JA and Lakhani SR: Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis 32: 650-658, 2011.
36. Blick T, Hugo H, Widodo E, Waltham M, Pinto C and Mani SA: Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24(lo/) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 15: 235-252, 2010.